Centerview SF Biotech - Quality of Exits?

Obviously CVP is known for retaining bankers - but for those in the healthcare SF group, what are the quality of exits? Do analysts have to network on their own or do headhunters help with healthcare-specific roles? Do analysts get looks at biotech crossover/hedge funds?

2 Comments
 

Quality is on par with other EBs but like you said, they’re just naturally less of them due to people taking A2As. You’re not going to get more or less attention from HH if that’s your concern

 

Dolores hic aperiam nulla voluptatum. Amet labore autem totam quam illo atque praesentium. Expedita alias unde consequuntur vitae. Veritatis iste molestiae animi dolorem. Eaque et ratione eum blanditiis neque.

Career Advancement Opportunities

July 2026 Investment Banking

  • Evercore 01 99.4%
  • Moelis & Company 01 98.9%
  • JPMorgan 01 98.3%
  • Guggenheim Partners 01 97.7%
  • Morgan Stanley 07 97.1%

Overall Employee Satisfaction

July 2026 Investment Banking

  • Moelis & Company No 99.4%
  • Evercore No 98.8%
  • Morgan Stanley 01 98.3%
  • BMO Capital Markets 13 97.7%
  • Banco Santander 01 97.1%

Professional Growth Opportunities

July 2026 Investment Banking

  • Evercore 01 99.4%
  • Moelis & Company 01 98.9%
  • Morgan Stanley 06 98.3%
  • Goldman Sachs 01 97.7%
  • JPMorgan 01 97.1%

Total Avg Compensation

July 2026 Investment Banking

  • Vice President (15) $434
  • Associates (46) $258
  • 3rd+ Year Analyst (8) $210
  • 2nd Year Analyst (22) $179
  • Intern/Summer Associate (13) $156
  • 1st Year Analyst (80) $150
  • Intern/Summer Analyst (73) $101
notes
16 IB Interviews Notes

“... there’s no excuse to not take advantage of the resources out there available to you. Best value for your $ are the...”

Leaderboard

success
From 10 rejections to 1 dream investment banking internship

“... I believe it was the single biggest reason why I ended up with an offer...”